[Neuropharmacological overview - 2012].
Daniel
D
Bereczki
D000284:Administration, Oral; D000779:Anesthetics, Local / Q000008:administration & dosage; D000925:Anticoagulants / Q000494:pharmacology* / Q000627:therapeutic use; D000927:Anticonvulsants / Q000494:pharmacology* / Q000627:therapeutic use; D002545:Brain Ischemia / Q000150:complications; D002986:Clinical Trials as Topic; D004827:Epilepsy / Q000188:drug therapy*; D006801:Humans; D007155:Immunologic Factors / Q000494:pharmacology* / Q000627:therapeutic use; D007166:Immunosuppressive Agents / Q000494:pharmacology; D020300:Intracranial Hemorrhages / Q000150:complications; D009103:Multiple Sclerosis / Q000188:drug therapy; D009480:Neuropharmacology / Q000639:trends*; D010300:Parkinson Disease / Q000188:drug therapy; D011322:Primary Prevention / Q000379:methods; D055502:Secondary Prevention / Q000379:methods; D020521:Stroke / Q000188:drug therapy* / Q000209:etiology / Q000517:prevention & control*; D015912:Thrombolytic Therapy / Q000379:methods*
D000779:Anesthetics, Local; D000925:Anticoagulants; D000927:Anticonvulsants; D007155:Immunologic Factors; D007166:Immunosuppressive Agents